Deutsche Bank
PRVL

Deutsche Bank’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Deutsche Bank’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,768
Closed -$248K – 4809
2020
Q4 		$248K Buy
10,768
+2,886
+37% +$36.6K ﹤0.01% 3349
2020
Q3 		$80K Buy
7,882
+688
+10% +$9.23K ﹤0.01% 3655
2020
Q2 		$107K Buy
7,194
+2,151
+43% +$33.1K ﹤0.01% 3401
2020
Q1 		$61K Buy
5,043
+2,468
+96% +$39.3K ﹤0.01% 3457
2019
Q4 		$40K Buy
2,575
+516
+25% +$6.58K ﹤0.01% 4067
2019
Q3 		$25K Buy
+2,059
New +$23.3K ﹤0.01% 4247

Deutsche Bank's PRVL Position: Q1 2021 in Review

Deutsche Bank sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 10,768 shares — an estimated $248K sold.

Deutsche Bank first reported a position in PRVL in Q3 2019 and held it in 6 quarters. The position peaked at $248K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Deutsche Bank reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Deutsche Bank sold 10,768 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $248K.
  • Deutsche Bank first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2019 and held it in 6 quarters.
  • Deutsche Bank's Prevail Therapeutics Inc. Common Stock position peaked at $248K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Deutsche Bank's 13F filing for Q1 2021, filed 13 May 2021.